Interaction of xenobiotics with myocardial signal transduction pathways

Cardiovascular Toxicology

Volumn 2, Issue 1, 2002, Pages 1-23

  Melchert, Russell B ^a   Joseph, Jacob ^b   Kennedy, Richard H ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Division of Cardiology   (United States)

Author keywords

Apoptosis; Cardiac fibroblasts; Cardiac myocytes; Cardiotoxicity; Heart; Hypertrophy; Signal transduction; Xenobiotics

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CALCINEURIN; CARDIOTROPHIN 1; CASPASE; CERAMIDE; COCAINE; CORTICOSTEROID; CORTICOSTERONE; CYTOKINE; DAUNORUBICIN; DEXFENFLURAMINE; DOXORUBICIN; FENFLURAMINE; FLUOROURACIL; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PHENTERMINE; PROTEIN KINASE C; PROTEIN P53; SIMVASTATIN; SOMATOMEDIN C; STEROID HORMONE; THYROID HORMONE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; XENOBIOTIC AGENT; ZALCITABINE; ZIDOVUDINE; HORMONE; ION CHANNEL;

ADULT; ANIMAL CELL; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL DEATH; CELL GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA CONTENT; DOUBLE BLIND PROCEDURE; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FETUS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART ARRHYTHMIA; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HORMONE ACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL; NEWBORN; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER; SEX DIFFERENCE; SIGNAL TRANSDUCTION; VALVULAR HEART DISEASE; ANIMAL; CYTOLOGY; DRUG EFFECT; EXTRACELLULAR MATRIX; HEART; HEART MUSCLE; PHYSIOLOGY;

ANIMALIA; JANUS;

ANIMALS; EXTRACELLULAR MATRIX; HEART; HORMONES; HUMANS; ION CHANNELS; MYOCARDIUM; SIGNAL TRANSDUCTION; XENOBIOTICS;

EID: 0036043270     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/ct:2:1:01     Document Type: Review

References (125)

1. Hefti, M.A., Harder, B.A., Eppenberger, H.M., and Schaub, M.C. (1997). Signaling pathways in cardiac myocyte hypertrophy. J. Mol. Cell. Cardiol. 29:2873-2892.
2. Yamazaki, T., Komuro, I., and Yazaki, Y. (1998). Signalling pathways for cardiac hypertrophy. Cell. Signal. 10:693-698.
3. Melchert, R.B., Yuan, C., and Acosta, D. (2001). Cardiovascular toxicology: introductory notes, in Cardiovascular Toxicology, 3rd ed. (D. Acosta, Jr., ed.), pp. 3-30, Taylor & Francis, New York.
4. Poelmann, R.E., Molin, D., Wisse, L.J., and Gittenbergerde Groot, A.C. (2000). Apoptosis in cardiac development. Cell Tissue Res. 301:43-52.
5. Narula J., Kharbanda, S., and Khaw, B.-A. (1997). Apoptosis and the heart. Chest 112:1358-1362.
6. Simpson, P., McGrath, A., and Savion, S. (1982). Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and catecholamines. Circ. Res. 51:787-801.
7. Sheng, Z., Knowlton, K., Chen, J., Hoshijima, M., Brown, J.H., and Chien, K.R. (1997). Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. J. Biol. Chem. 272:5783-5791.
8. Liu, Y., Leri,A.,Li, B., et al. (1998). Angiotensin II stimulation in vitro induces hypertrophy of normal and postinfarcted ventricular myocytes. Circ. Res. 82:1145-1159.
9. Kajstura,J., Cigola, E., Malhotra, A., et al. (1997). Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J. Mol. Cell. Cardiol. 29:859-870.
10. Krown, K.A., Page, M.T., Nguyen, C., et al. (1996). Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J. Clin. Invest. 98:2854-2865.
11. Nakamura, K., Fushimi, K., Kouchi, H., et al. (1998). Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II. Circulation 98:794-799.
12. Sadoshima, J.-I. and Izumo, S. (1993). Mechanical stretch rapidly activates multiple signal transduction pathways in cardiac myocytes: potential involvement of an autocrine/paracrine mechanism. EMBO J. 12:1681-1692.
13. Paradis, P., MacLellan, W.R., Belaguli, N.S., Schwartz, R.J., and Schneider, M.D. (1996). Serum response factor mediates AP-1-dependent induction of the skeletal α-actin promoter in ventricular myocytes. J Biol. Chem. 271:10,827-10,833.
14. Kent, R.L. and McDermott, P.J. (1996). Passive load and angiotensin II evoke differential responses of gene expression and protein synthesis in cardiac myocytes. Circ. Res. 78:829-838.
15. Gray, M.O., Long, C.S., Kalinyak, J.E., Li, H.T., and Karliner, J.S. (1998). Angiotensin II stimulates cardiomyocyte hypertrophy via paracrine release of TGF-β1 and endothelin-1 from fibroblasts. Cardiovasc. Res. 40:352-363.
16. Komuro, I., Kudo, S., Yamazaki, T., Zou, Y., Shiojima, I., and Yazaki, Y. (1996). Mechanical stretch activates the stress-activated protein kinases in cardiac myocytes. FASEB J. 10:631-636.
17. Molkentin, J.D., Lu, J.R., Antos, C.L., et al. (1998). A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215-228.
18. Touyz, R.M., Sventek, P., Lariviere, R., et al. (1996). Cytosolic calcium changes induced by angiotensin II in neonatal rat atrial and ventricular cardiomyocytes are mediated via angiotensin II subtype 1 receptors. Hypertension 27:1090-1096.
19. 2-terminal kinase activation in the heart. Crosstalk between cardiac hypertrophic signaling pathways. J. Biol. Chem. 275:13,571-13,579.
20. Sato, A. and Funder, J.W. (1996). High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 137:4145-4153.
21. Puceat, M., Hilal-Dandan, R., Strulovici, B., Brunton, L.L., and Brown, J.H. (1994). Differential regulation of protein kinase C isoforms in isolated neonatal and adult rat cardiomyocytes. J. Biol. Chem. 269:16,938-16,944.
22. Yamazaki, T., Komuro, I., Kudoh, S., et al. (1996). Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J. Biol. Chem. 271:3221-3228.
23. Kunisada, K., Hirota, H., Fujio, Y., et al. (1996). Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp 130 in cardiac myocytes. Circulation 94:2626-2632.
24. Post, G.R., Goldstein, D., Thuerauf, D.J., Glembotski, C.C., and Brown, J.H. (1996). Dissociation of p44 and p42 mitogen-activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes. J. Biol. Chem. 271:8452-8457.
25. Kudoh, S., Komuro, I., Mizuno, T., et al. (1997). Angiotensin II stimulates c-jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ. Res. 80:139-146.
26. Coroneos, E., Wang, Y., Panuska, J.R., Templeton, D.J., and Kester, M. (1996). Sphingolipid metabolites differentially regulate extracellular signal-regulated kinase and stress-activated protein kinase cascades. Biochemical J. 316:13-17.
27. Wang, Y., Huang, S., Sah, V.P., et al. (1998). Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J. Biol. Chem. 273:2161-2168.
28. ++ concentrations. J. Biol. Chem. 275:27,838-27,844.
29. Sussrnan, M.A., Lim, H.W., Gude, N., et al. (1998). Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281:1690-1693.
30. Amin, J.K., Xiao, L., Pimental, D.R., et al. (2001). Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol. Cell. Cardiol. 33:131-139.
31. Luo, J.-D., Xie, F., Zhang, W.-W., Ma, X.-D., Guan, J.-X., and Chen, X. (2001). Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br. J. Pharmacol. 132:159-164.
32. Marsh, J.D., Lehmann, M.H., Ritchie, R.H., Gwathmey, J.K., Green, G.E., and Schiebinger, R.J. (1998)., androgen receptors mediate hypertrophy in cardiac myocytes. Circulation 98:256-261.
33. LaMear, N.S., MacGilvray, S.S., and Myers, T.F. (1997). Dexamethasone-induced myocardial hypertrophy in neonatal rats. Biol. Neonate 72:175-180.
34. Shioi, T., Kang, P.M., Douglas, P.S., et al. (2000). The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19:2537-2548.
35. Goldberg, Y.,Taimor, G., Piper, H.M., and Schluter, K.-D. (1998). Intracellular signaling leads to the hypertrophic effect of neuropeptide Y. Am. J. Physiol. 275:C1207-C1215.
36. Sun, H.Y, Zhao, R.R., and Zhi, J.M. (2000). Insulin-like growth factor I inhibits cardiomyocyte apoptosis and the underlying signal transduction pathways. Methods Findings Exp. Clin. Pharmacol. 22:601-607.
37. Sugden, H.C. and Clerk, A. (2001). Akt like a woman. Gender differences in susceptibility to cardiovascular disease. Circulation 88:975-977.
38. Matsui, T., Li, L., del Monte, F., et al. (1999). Adenoviral gene transfer of activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 100:2373-2379.
39. Wu, W., Lee, W.L., Wu, Y.Y., et al. (2000). Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells. J. Biol. Chem. 275:40,113-40,119.
40. Fujio, Y., Nguyen, T., Wencker, D., Kitsis, R.N., and Walsh, K. (2000). Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101:660-667.
41. Wu, C.F., Bishopric, N.H., and Pratt, R.E. (1997). Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J. Biol. Chem. 272:14,860-14,866.
42. Sawyer, D.B., Fukazawa, R., Arstall, M.A., and Kelly, R.A. (1999). Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ. Res. 84:257-265.
43. Communal, C., Singh, K., Pimentel, D.R., and Colucci, W.S. (1998). Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation 98:1329-1334.
44. Geng, Y.J., Ishikawa, Y., Vatner, D.E., et al. (1999). Apoptosis of cardiac myocytes in Gs alpha transgenic mice. Circ. Res. 84:34-42.
45. Shizukuda, Y., Buttrick, P.M., Geenen, D.L., et al. (1998). Beta-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am. J Physiol. 275:H961-H968.
46. Long, X., Boluyt, M.O., Hipolito, M.L., et al. (1997). p53 and the hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes. J. Clin. Invest. 99:2635-2643.
47. Schulze-Osthoff, K., Ferrari, D., Los, M., Wesselborg, S., and Peter, M.E. (1998). Apoptosis signaling by death receptors. Eur. J. Biochem. 254:439-459.
48. 2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 100:2210-2212.
49. Zhu, W., Zou, Y., Aikawa, R., et al. (1999). MAPK super-family plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation 100:2100-2107.
50. Kang, Y.J., Zhou, Z.-X., Wang, G.W., Buridi, A., and Klein, J.B. (2000). Suppression by metallothionein of doxo-rubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J. Biol. Chem. 275:13,690-13,698.
51. Yue, T.L., Wang, C., Gu, J.L., et al. (2000). Inhibition of extracellular signal-regulated kinase enhances ischemia/ reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ. Res. 86:692-699.
52. Kluck, R.M., Bossy-Wetzel, E., Green, D.R., and Newmeyer, D.D. (1997). The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275:1132-1136.
53. Li, F., Srinivasan, A., Wang, Y., Armstrong, R.C., Tomaselli, K.J., and Fritz, L.C. (1997). Cell-specific induction of apoptosis by microinjection of cytochrome c. J. Biol. Chem 72:30,299-30,305.
54. Staunton, M.J. and Gaffney, E.F. (1998). Apoptosis: basic concepts and potential significance in human cancer. Arch. Pathol. Lab. Med. 122:310-319.
55. Bialik, S., Cryns, V,L., Drincic, A., et al. (1999). The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ. Res. 85:403-414.
56. von Harsdorf, R., Li, P.F., and Dietz, R. (1999). Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 99:2934-2941.
57. Clarke, A.R.C.A., Purdie, D.J., Harrison, D.J., et al. (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852.
58. Lowe, S.W., Ruley, H.E., Jacks, T., and Housman, D.E. (1993). p53-independent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell 74:957-967.
59. Selvakumaran, M., Lin, H.K., Miyashita, T., et al. (1994). Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathway. Oncogene 9:1791-1798.
60. Polyak, K., Xia, Y., Zweier, J.L., Kinzler, K.W., and Vogelstein, B. (1997). A model for p53-induced apoptosis. Nature 389:300-305.
61. Fuchs, E.J., McKenna, K.A., and Bedi, A. (1997). p53-dependent DNA damage-induced apoptosis requires Fas/ APO-1-independent activation of CPP32b. Cancer Res. 57:2550-2554.
62. Andrieu-Abadie, N., Jaffrezou, J.P., Hatem, S., Laurent, G., Levade, T., and Mercaider, J.J. (1999). L-Carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. FASEB J. 13:1501-1510.
63. Kinloch, R.A., Treheme, J.M., Furness, L.M., and Hajimohamadreza, I. (1999). The pharmacology of apoptosis. Trends Pharmacol. Sci. 20:35-42.
64. Green, D. (1998). Apoptotic pathways: the roads to ruin. Cell 94:695-698.
65. Ollinger, K. (2000). Inhibition of cathepsin D prevents freeradical-induced apoptosis in rat cardiomyocytes. Arch. Biochem. Biophys. 373:346-351.
66. Yue, T.L., Wang, C., Romanic, A.M., et al. (1998). Staurosporine-induced apoptosis in cardiomyocyes: a potential role of caspase-3. J. Mol. Cell. Cardiol. 30:495-507.
67. Shneyvays, V., Jacobson, K.A., Li, A.H., et al. (2000). Induction of apoptosis in rat cardiocytes by A3 adenosine receptor activation and its suppression by isoproterenol. Exp. Cell Res. 257:111-126.
68. McHowat, J., Swift, L.M., Arutunyan, A., and Sarvazyan, N. (2001). Clinical concentrations of doxorubicin inhibit activity of myocardial membrane-associated, calcium-independent phospholipase A2. Cancer Res. 61:4024-4029.
69. Maeda, A., Honda, M., Kuramochi, T., and Takabatake, T. (1998). Doxorubicin cardiotoxicity: diastolic cardiac myocyte dysfunction as a result of impaired calcium handling in isolated cardiac myocytes. Jpn. Circ. J. 62:505-511.
70. Al-Nasser, I.A. (1998). In vivo prevention of adriamycin cardiotoxicity by cyclosporin A or FK506. Toxicology 131:175-181.
71. Kunisada, K., Negoro, S., Tone, E., et al. (2000). Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc. Natl. Acad. Sci. USA 97:315-319.
72. Suzuki, T. and Miyauchi, T. (2001). A novel pharmacological action of ET-1 to prevent the cytotoxicity of doxorubicin in cardiomyocytes. Am. J Physiol. 280:R1399-R1406.
73. Iliskovic, N. and Singal, P.K. (1997). Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am. J. Pathol. 150:727-734.
74. Sacco, G., Bigioni, M., Evangelista, S., Goso,C., Manzini, S., and Maggi, C.A. (2001). Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur. J. Pharmacol. 414:71-78.
75. Wang, L., Ma, W., Markovich, R., Chen, J.W., and Wang, P.H. (1998). Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ. Res. 83:516-522.
76. Arola, O.J., Saraste, A., Pulkki, K., Kallajoki, M., Parvinen, M., and Voipio-Pulkki, L.M. (2000). Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 60:1789-1792.
77. Yin, X., Wu, H., Chen, Y., and Kang, Y.J. (1998). Induction of antioxidants by adriamycin in mouse heart. Biochem. Pharmacol. 56:87-93.
78. Boucek, R.J., Miracle, A., Anderson, M., Engelman, R., Atkinson, J., and Dodd, D.A. (1999). Persistent effects of doxorubicin on cardiac gene expression. J Mol. Cell. Cardiol. 31:1435-1446.
79. Weinstein, D.M., Mihm, M.J., and Bauer, J.A. (2000). Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J. Pharmacol. Exp. Ther. 294:396-401.
80. Kumar, D., Kirshenbaum, L.A., Li, T., Danelisen, I., and Singal, P.K. (2001). Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxidants Redox Signaling 3:135-145.
81. Xiao, Y., He, J., Gilbert, R.D., and Zhang, L. (2000). Cocaine induces apoptosis in fetal myocardial cells through a mitochondria-dependent pathway. J. Pharmacol. Exp. Ther. 292:8-14.
82. Zhang, L., Xiao, Y., and He, J. (1999). Cocaine and apoptosis in myocardial cells. Anat. Rec. 257:208-216.
83. Besse, S., Assayag, P., Latour, C., et al. (1997). Molecular characteristics of cocaine-induced cardiomyopathy in rats. Eur. J. Pharmacol. 338:123-129.
84. Kashiwagi, Y., Haneda, T., Osaki, J., Miyata, S., and Kikuchi, K. (1998). Mechanical stretch activates a pathway linked to mevalonate metabolism in cultured neonatal rat heart cells. Hypertens. Res. 21:109-119.
85. Oi, S., Haneda, T., Osaki, J., et al. (1999). Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur. J. Pharmacol. 376:139-148.
86. Melchert, R.B., Liu, H., Granberry, M.C., and Kennedy, R.H. (2001). Lovastatin inhibits phenylephrine-induced ERK activation and growth of cardiac myocytes. Cardiovasc. Toxicol. 1:237-252.
87. Luo, J.D., Zhang, W.W., Zhang, G.P., Guan, J.X., and Chen, X. (1999). Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin. Exp. Pharmacol. Physiol. 26:903-908.
88. Patel, R., Nagueh, S.F., Tsybouleva, N., et al. (2001). Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104:317-324.
89. Satoh, K., Shirota, F., Tsunajima, T., Beinlich, C.J., Morgan, H.E., and Ichihara, K. (2001). Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: comparison with pravastatin. Am. J. Physiol. Heart Circ. Physiol. Ph 280:H2746-H2751.
90. Satoh, K. and Ichihara, K. (1995). Effects of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts. Eur. J Pharmacol. 292:271-275.
91. Melchert, R.B., Kennedy, R.H., and Acosta, D. (2001). Cardiovascular effects of steroidal agents, in Cardiovascular Toxicology, 3rd ed. (D. Acosta, Jr., ed.), pp. 425-475, Taylor & Francis, New York.
92. Pelzer, T., Schumann, M., Neumann, M., et al. (2000). 17 beta-estradiol prevents programmed cell death in cardiac myocytes. Biochem. Biophys. Res. Commun. 268:192-200.
93. de Jager, T., Pelzer, T., Muller-Botz, S., Imam, A., Muck, J., and Neyses, L. (2001). Mechanisms of estrogen receptor action in the myocardium. Rapid gene activation via the ERKI/2 pathway and serum response elements. J Biol. Chem. 276:27,873-27,880.
94. Camper-Kirby, D., Welch, S., Walker, A., et al. (2001). Myocardial Akt activation and gender. Increased nuclear activity in females versus males. Circ. Res. 88:1020-1027.
95. Grohe, C., Kahlert,S., Lobbert, K., et al. (1997). Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett. 416:107-112.
96. Sharma, A., Plessinger, M.A., Miller, R.K., and Woods, J.R. (1993). Progesterone antagonist mifepristone (RU 486) decreases cardiotoxicity of cocaine. Proc. Soc. Exp. Biol. Med. 202:279-287.
97. Kurtzman, J.T., Thorp, J.M., Spielman, F.J., Perry, S., Mueller, R.A., and Cefalo, R.C. (1994). Estrogen mediates the pregnancy-enhanced cardiotoxicity of cocaine in the isolated perfused rat heart. Obstet. Gynecol. 83:613-615.
98. Durak, I., Karaayvaz, M., Kavutcu, M., et al. (2000). Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. J. Toxicol. Environ. Health 59:585-589.
99. Lewis, W., Grupp, I.L., Grupp, G., et al. (2000). Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab. Invest. 80:187-197.
100. Skuta, G., Fischer, G.M., Janaky, T., et al. (1999). Molecular mechanism of the short-term cardiotoxicity caused by 2′,3′-dideoxycytidine (ddC): modulation of reactive oxygen species levels and ADP-ribosylation reactions. Biochem. Pharmacol. 58:1915-1925.
101. Liang, B.T. and Jacobson, K.A. (1998). A physiological role fo the adenosine A3 receptor: sustained cardioprotection. Proc. Natl. Acad. Sci. USA 95:6995-6999.
102. Walker, M.K. and Catron, T.F. (2000). Characterization of cardiotoxicity induced by 2,3,7,8-tetrachlorodibenzop-dioxin and related chemicals during early chick embryo development. Toxicol. Appl. Pharmacol. 167:210-221.
103. Fernandez-Salguero, P.M., Ward, J.M., Sundberg, J.P., and Gonzalez, F.J. (1997). Lesions of aryl-hydrocarbon receptor-deficient mice. Vet. Pathol. 34:605-614.
104. Slotkin, T.A., Pinkerton, K.E., Garofolo, M.C., Auman, J.T., McCook, E.C., and Seidler, F.J. (2001). Perinatal exposure to environmental tobacco smoke induces adenylyl cyclase and alters receptor-mediated cell signaling in brain and heart of neonatal rats. Brain Res. 898:73-81.
105. Weber, K.T. and Brilla, C.G. (1991). Pathological hypertrophy and the cardiac interstititum: fibrosis and renin-angiotensin-aldosterone system. Circulation 83:1849-1865.
106. Toyoda, Y. Okada, M., and Kashem, M.A. (1998). A canin model of dilated cardiomyopathy induced by repetitive intracoronary doxorubicin administartion. J Thorac. Cardiovasc. Surg. 115:1367-1373.
107. Shug, A.L. (1987). Protection from adriamycin-induced cardiomyopathy in rats. Z. Kardiol. 76:46-52.
108. Fitter, W., deSa, D.J., and Pai, K.R. (1981). Adriamycin cardiotoxicity: report of an unusual case with features resembling endomyocardial fibrosis. J. Clin. Pathol. 34:602-605.
109. Van den Branden, C., Ceyssens, B., De Craemer, D., et al. (2000). Renal antioxidant enzymes and fibrosis-related markers in the rat adriamycin model. Nephron 86:167-175.
110. Griffin, M., Lee, H.W., Zhao, L., and Eghblai-Webb, M. (2000). Gender-related differences in proliferative response of cardiac fibroblasts to hypoxia. Mol. Cell Biochem. 215:21-30.
111. Lee, H.W. and Eghbali-Webb, M. (1998). Estrogen enhances proliferative capacity of cardiac fibroblasts by estrogen receptor- and mitogen-activated protein kinase-dependent pathways. J. Mol. Cell. Cardiol. 30:1359-1368.
112. Grohe, C., Kahlert, S., Lobbert, K., et al. (1996). Modulation of hypertensive heart disease by estrogen. Steroids 61:201-204.
113. Dubey, R.K., Gillespie, D.G., Jackson, E.K., and Keller, P.J. (1998). 17 Beta-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension 31:522-528.
114. Young, M., Fullerton, M., Dilley, R., and Funder, J. (1994). Mineralocorticoids, hypertension, and cardiac fibrosis. J. Clin. Invest. 93:2578-2583.
115. Brilla, C.G., Pick, R., Tan, L.B., Janicki, J.S., and Weber, K.T. (1990). Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res. 67:1355-1364.
116. Robert, V., Van Thiem, N., Cheav, S.L., Mouas, C., Swynghedauw, B., and Delcayre, C. (1994). Increased cardiac types I and III collagen mRNAs in aldosteronesalt hypertension. Hypertension 24:30-36.
117. Brilla, C.G., Zhou, G., Matsubara, L., and Weber, K.T. (1994). Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J. Mol. Cell. Cardiol. 26:809-820.
118. Henzlova, M.J., Smith, S.H., Prchal, V.M., and Helmcke, F.R. (1991). Apparent reversibility of cocaine-induced congestive cardiomyopathy. Am. Heart J. 122:577-579.
119. Kneupfer, M.M., Branch, C.A., Gan, Q., and Fischer, V.W. (1993). Cocaine-induced myocardial ultrastructural alterations and cardiac output responses in rats. Exp. Mol. Pathol. 59:155-168.
120. Jick, H., Vasilakis, C., Weinrauch, L.A., Meier, C.R., Jick, S.S., and Derby, L.E. (1998). A population-based study of appetite -suppressant drugs and the risk of cardiac valve regurgitation. N. Engl. J. Med. 339:719-724.
121. Khan, M.A., Herzog, C.A., St. Peter, J.V., et al. (1998). The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N. Engl. J. Med. 339:713-718.
122. Jollis, J.G., Landolfo, C.J., Kisslo, J., Constantine, G.D., Davis, K.D., and Ryan, T. (2000). Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 101:2071-2077.
123. Davidoff, R., McTiernan, A., Constantine, G., et al. (2001). Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. Arch. Intern. Med. 161:1429-1436.
124. Fitzgerald, L.W., Burn, T.C., Brown, B.S., et al. (2000). Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfiuramine. Mol. Pharmacol. 57:75-81.
125. Rothman, R.B., Baumann, B.H., Savage, J.E., et al. (2000). Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotoninergic medications. Circulation 102:2836-2841.